Literature DB >> 12877759

Cardiovascular manifestations of substance abuse: part 2: alcohol, amphetamines, heroin, cannabis, and caffeine.

William H Frishman1, Alexander Del Vecchio, Shirin Sanal, Anjum Ismail.   

Abstract

The abuse of alcohol is associated with chronic cardiomyopathy, hypertension, and arrhythmia. Abstinence or using alcohol in moderation can reverse these cardiovascular problems. Alcohol is also distinguished among the substances of abuse by having possible protective effects against coronary artery disease and stroke when used in moderate amounts. Amphetamines (eg, speed, ice, ecstasy) have many of the cardiovascular toxicities seen with cocaine, including acute and chronic cardiovascular diseases. Heroin and other opiates can cause arrhythmias and noncardiac pulmonary edema, and may reduce cardiac output. Cardiovascular problems are less common with cannabis (marijuana) than with opiates, but major cognitive disorders may be seen with its chronic use. It is still controversial whether caffeine can cause hypertension and coronary artery disease, and questions have been raised about its safety in patients with heart failure and arrhythmia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12877759     DOI: 10.1097/01.hdx.0000080713.09303.a6

Source DB:  PubMed          Journal:  Heart Dis        ISSN: 1521-737X


  33 in total

Review 1.  Energy beverages: content and safety.

Authors:  John P Higgins; Troy D Tuttle; Christopher L Higgins
Journal:  Mayo Clin Proc       Date:  2010-11       Impact factor: 7.616

Review 2.  Potential adverse effects of amphetamine treatment on brain and behavior: a review.

Authors:  S M Berman; R Kuczenski; J T McCracken; E D London
Journal:  Mol Psychiatry       Date:  2008-08-12       Impact factor: 15.992

3.  Exercise stress testing in recently abstinent chronic cocaine abusers.

Authors:  Praveen Kanneganti; Richard A Nelson; Susan J Boyd; Roy C Ziegelstein; David A Gorelick
Journal:  Am J Drug Alcohol Abuse       Date:  2008       Impact factor: 3.829

4.  Depression and its association with adverse childhood experiences in people with substance use disorders and comorbid medical illness recruited during medical hospitalization.

Authors:  Helene L Philogene-Khalid; Eric Cunningham; Daohai Yu; Jaclyn E Chambers; Adam Brooks; Xiaoning Lu; Mary F Morrison
Journal:  Addict Behav       Date:  2020-06-04       Impact factor: 3.913

5.  Factors Influencing the Frequency of Emergency Department Utilization by Individuals with Substance Use Disorders.

Authors:  Christophe Huynh; Francine Ferland; Nadine Blanchette-Martin; Jean-Marc Ménard; Marie-Josée Fleury
Journal:  Psychiatr Q       Date:  2016-12

6.  Older methadone patients achieve greater durations of cocaine abstinence with contingency management than younger patients.

Authors:  Lindsay Weiss; Nancy M Petry
Journal:  Am J Addict       Date:  2013-02-01

7.  Kinetic and cardiovascular effects of acute topiramate dosing among non-treatment-seeking, methamphetamine-dependent individuals.

Authors:  Bankole A Johnson; Lynda T Wells; John D Roache; Christopher L Wallace; Nassima Ait-Daoud; Michael A Dawes; Lei Liu; Xin-Qun Wang; Martin A Javors
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2006-12-19       Impact factor: 5.067

8.  Identifying and Addressing the Unmet Health Care Needs of Drug Court Clients.

Authors:  Karen L Dugosh; David S Festinger; Jessica L Lipkin
Journal:  J Subst Abuse Treat       Date:  2016-08-28

9.  Identifying patients with problematic drug use in the emergency department: results of a multisite study.

Authors:  Wendy L Macias Konstantopoulos; Jessica A Dreifuss; Katherine A McDermott; Blair Alden Parry; Melissa L Howell; Raul N Mandler; Garrett M Fitzmaurice; Michael P Bogenschutz; Roger D Weiss
Journal:  Ann Emerg Med       Date:  2014-07-03       Impact factor: 5.721

Review 10.  At the bottom of the differential diagnosis list: unusual causes of pediatric hypertension.

Authors:  Matthew M Grinsell; Victoria F Norwood
Journal:  Pediatr Nephrol       Date:  2008-03-05       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.